Abstract
A novel zoledronate derivative, 1-hydroxy-4-(2-butyl-1H-imidazol-1-yl)butane-1,1- diyldiphosphonic acid (BIBDP) was prepared and labeled with 99mTc successfully in a high radiochemical purity and good stability in vitro. The biodistribution in mice shows that 99mTc-BIBDP has high specificity and efficacy in bone uptake with a maximum of 12.14 ± 0.53 %ID/g at 120 min. Kinetics of blood clearance showed that distribution half life (T1/2α), elimination half life (T1/2β) and total clearance rate (CL) of 99mTc-BIBDP were 4.67 min, 91.9 min and 1.21 %ID/g·min-1, respectively. Moreover, 99mTc-BIBDP has higher uptake in the bone and faster clearance from soft tissues than 99mTc-MDP and 99mTc-ZL. A plain and clear bone image was obtained at 1 h with SPECT bone imaging. The present findings indicate that 99mTc- BIBDP holds great potential for bone imaging.
Keywords: Diphosphonic acid, 99mTc-labeled, Biodistribution, Pharmacokinetics, SPECT imaging
Current Radiopharmaceuticals
Title:A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation
Volume: 6 Issue: 1
Author(s): Ling Qiu, Wen Cheng, Jianguo Lin, Shu Zhang and Shineng Luo
Affiliation:
Keywords: Diphosphonic acid, 99mTc-labeled, Biodistribution, Pharmacokinetics, SPECT imaging
Abstract: A novel zoledronate derivative, 1-hydroxy-4-(2-butyl-1H-imidazol-1-yl)butane-1,1- diyldiphosphonic acid (BIBDP) was prepared and labeled with 99mTc successfully in a high radiochemical purity and good stability in vitro. The biodistribution in mice shows that 99mTc-BIBDP has high specificity and efficacy in bone uptake with a maximum of 12.14 ± 0.53 %ID/g at 120 min. Kinetics of blood clearance showed that distribution half life (T1/2α), elimination half life (T1/2β) and total clearance rate (CL) of 99mTc-BIBDP were 4.67 min, 91.9 min and 1.21 %ID/g·min-1, respectively. Moreover, 99mTc-BIBDP has higher uptake in the bone and faster clearance from soft tissues than 99mTc-MDP and 99mTc-ZL. A plain and clear bone image was obtained at 1 h with SPECT bone imaging. The present findings indicate that 99mTc- BIBDP holds great potential for bone imaging.
Export Options
About this article
Cite this article as:
Qiu Ling, Cheng Wen, Lin Jianguo, Zhang Shu and Luo Shineng, A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation, Current Radiopharmaceuticals 2013; 6 (1) . https://dx.doi.org/10.2174/1874471011306010005
DOI https://dx.doi.org/10.2174/1874471011306010005 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
Current Medicinal Chemistry Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Letters in Drug Design & Discovery Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery On the Design of Broad Based Screening Assays to Identify Potential Pharmacological Chaperones of Protein Misfolding Diseases
Current Topics in Medicinal Chemistry Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Advances in Clinical Study of Curcumin
Current Pharmaceutical Design Computer-Aided Drug Design for Cancer-Causing H-Ras p21 Mutant Protein
Letters in Drug Design & Discovery Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity
Current Cancer Therapy Reviews Use of Mesenchymal Stem Cells in Crohn's Disease and Perianal Fistulas: A Narrative Review
Current Stem Cell Research & Therapy Transmission Electron Microscopy as Key Technique for the Characterization of Telocytes
Current Stem Cell Research & Therapy Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews Withdrawal Notice: Electrophoresis as a Tool for Early Cancer Diagnosis
Anti-Cancer Agents in Medicinal Chemistry Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Epothilones: From Discovery to Clinical Trials
Current Topics in Medicinal Chemistry Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening p38 MAPK: A Potential Target of Chronic Pain
Current Medicinal Chemistry